Ligation of CM1 enhances apoptosis of lung cancer cells through different mechanisms in conformity with EGFR mutation
暂无分享,去创建一个
G. Park | YeongSeok Kim | Hyunkeun Song | D. Hur | V. Broaddus | Hyun‐Kyung Lee | YEONG SEOK KIM | V. Broaddus
[1] H. Hieronymus,et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR , 2011, Nature.
[2] Long-Sen Chang,et al. Piceatannol induces Fas and FasL up-regulation in human leukemia U937 cells via Ca2+/p38alpha MAPK-mediated activation of c-Jun and ATF-2 pathways. , 2010, The international journal of biochemistry & cell biology.
[3] Shu-guang Wang,et al. The Role of MAPK-ERK Pathway in 67-kDa Laminin Receptor-Induced FasL Expression in Human Cholangiocarcinoma Cells , 2010, Digestive Diseases and Sciences.
[4] K. Nishio,et al. Mitogen‐activated protein kinase phosphatase‐1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor‐tyrosine kinase , 2009, The FEBS journal.
[5] Susanna M Cramb,et al. The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] S. Wacholder,et al. Environment And Genetics in Lung cancer Etiology (EAGLE) study: An integrative population-based case-control study of lung cancer , 2008, BMC public health.
[7] D. Hicklin,et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non–small cell lung cancers , 2007, Molecular Cancer Therapeutics.
[8] D. Camidge. The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancer. , 2007, Clinical lung cancer.
[9] G. Park,et al. Ligation of centrocyte/centroblast marker 1 on Epstein-Barr virus--transformed B lymphocytes induces cell death in a reactive oxygen species--dependent manner. , 2006, Human immunology.
[10] G. Giaccone,et al. Cell Death Independent of Caspases: A Review , 2005, Clinical Cancer Research.
[11] A. A. Starkov,et al. Mitochondrial metabolism of reactive oxygen species , 2005, Biochemistry (Moscow).
[12] Michael Peyton,et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.
[13] P. Vandenabeele,et al. Activation of p38 MAPK is required for Bax translocation to mitochondria, cytochrome c release and apoptosis induced by UVB irradiation in human keratinocytes , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[14] N. Moldovan,et al. Oxygen free radicals and redox biology of organelles , 2004, Histochemistry and Cell Biology.
[15] R. Alexander,et al. Reactive oxygen species as mediators of angiogenesis signaling. Role of NAD(P)H oxidase , 2004, Molecular and Cellular Biochemistry.
[16] Keith M. Kerr,et al. Gene Expression Profiling in Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[17] Jorge A. Almenara,et al. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process , 2004, Oncogene.
[18] K. Reddy,et al. Role of MAP kinase in tumor progression and invasion , 2003, Cancer and Metastasis Reviews.
[19] H. Hansen. Treatment of advanced non-small cell lung cancer , 2002, BMJ : British Medical Journal.
[20] S. Terrazzino,et al. H2O2 induces upregulation of Fas and Fas ligand expression in NGF‐differentiated PC12 cells: Modulation by cAMP , 2002, Journal of neuroscience research.
[21] YeongSeok Kim,et al. CM1 ligation initiates apoptosis in a caspase 8-dependent manner in Ramos cells and in a mitochondria-controlled manner in Raji cells. , 2002, Human immunology.
[22] M. Campiglio,et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] John Mendelsohn,et al. The EGF receptor family as targets for cancer therapy , 2000, Oncogene.
[24] D. Hur,et al. CM1, a possible novel activation molecule on human lymphocytes. , 2000, Immunology letters.
[25] M. Macey,et al. Subcellular distribution and redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis. , 1999, Blood.
[26] C. Borner,et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c , 1998, Nature.
[27] M. V. Heiden,et al. Bcl-xL Regulates the Membrane Potential and Volume Homeostasis of Mitochondria , 1997, Cell.
[28] Dean P. Jones,et al. Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.
[29] S. Korsmeyer,et al. Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death , 1995, Cell.
[30] Matthews Ji,et al. Lung cancer. An update. , 1985 .
[31] Barry H. Smith,et al. A continuous tumor‐cell line from a human lung carcinoma with properties of type II alveolar epithelial cells , 1976, International journal of cancer.
[32] Sun-Mi Park,et al. CD95 promotes tumour growth , 2011, Nature.
[33] P. Jänne,et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. , 2005, Journal of the National Cancer Institute.
[34] I. Klyubin,et al. Roles of reactive oxygen species: signaling and regulation of cellular functions. , 1999, International review of cytology.